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Abstract
Arsenic toxicity is a global health problem affecting many millions of people. The main source of
exposure is drinking water contaminated by natural geological sources. Current risk assessment is
based on the recognized carcinogenicity of arsenic, but neurotoxic risks have been overlooked. In
1955, an outbreak of arsenic poisoning occurred among Japanese infants, with more than 100
deaths. The source was contaminated milk powder produced by the Morinaga company. Detailed
accounts of the Morinaga dried milk poisoning were published in Japanese only, and an overview of
this poisoning incident and its long-term consequences is therefore presented. From analyses
available, the arsenic concentration in milk made from the Morinaga milk powder is calculated to
be about 4–7 mg/L, corresponding to daily doses slightly above 500 μg/kg body weight. Lower
exposures would result from using diluted milk. Clinical poisoning cases occurred after a few weeks
of exposure, with a total dose of about 60 mg. This experience provides clear-cut evidence for
hazard assessment of the developmental neurotoxicity. At the present time, more than 600
surviving victims, now in their 50s, have been reported to suffer from severe sequelae, such as
mental retardation, neurological diseases, and other disabilities. Along with more recent
epidemiological studies of children with environmental arsenic exposures, the data amply
demonstrate the need to consider neurotoxicity as a key concern in risk assessment of inorganic
arsenic exposure.
Background
Arsenic toxicity is a global health problem affecting many
millions of people. The major source of human exposure
is contamination of drinking water from natural geologi-
cal sources, but anthropogenic emissions from mining,
smelting, or agricultural sources (pesticides or fertilizers)
also contribute to local exposures [1]. Although current
risk assessment is based on the recognized carcinogenicity
of arsenic [2,3], other adverse effects, such as neurotoxic-
ity, may also be relevant. For instance, peripheral neurop-
athy has been amply demonstrated in adults [4-6] and is
thought to occur only at fairly high exposure levels that
would already be deemed unacceptable from the view-
point of preventing arsenic-induced cancer. In past inci-
dents, 15 fatalities occurred among 500 patients exposed
to arsenic-contaminated wine in France in 1888; 70 of
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6,000 patients from arsenic-contaminated beer in Eng-
land in 1900–1901; and 15 of 28 patients due to arsenic-
contaminated cider in the US in 1924 [7]. These events
involved adults only.
Developmental processes in the nervous system are vul-
nerable to disruption by such chemicals at doses that may
not be toxic to mature systems [8-10], and consideration
of developmental neurotoxicity would therefore seem to
be appropriate. An extensive data base on developmental
arsenic toxicity exists from an unfortunate poisoning inci-
dent in Japan in the mid-1950s. The so-called Morinaga
dried milk poisoning has received only cursory coverage
in the English-language scientific literature, but detailed
accounts are available in Japanese. According to official
records, more than one hundred infants died from arsenic
poisoning [11], thus making the fatality rate of this food
poisoning incident the most serious one ever to occur in
Japan. In the absence of a detailed account in English, we
therefore present an overview of the Morinaga dried milk
poisoning based on reports published by Japanese
researchers.
Outbreak of Arsenic Poisoning in Japan
In the early summer 1955, physicians in the western part
of Japan became worried about outbreaks of an unusual
disease characterized by anorexia, skin pigmentation,
diarrhea, vomiting, fever, and abdominal distention
among infants, mostly less than 12 months of age [12,13].
In the beginning, before the etiology was recognized,
most general practitioners attributed these illnesses to
acute bronchitis or pneumonia and prescribed antibiotics,
such as penicillin or streptomycin [7]. Pediatricians at a
university hospital temporarily suspected Candida septi-
cemia, as presence of Candida albicans in urine and skin
was observed in some infants by microscopy. On August
20th, however, the autopsy on a 5-month-old infant did
not provide any verification of either visceral Candidiasis
or characteristic inflammatory changes in the liver.
As an apparent link, most of the patients were bottle-fed,
often using the popular Morinaga dried milk brand. In
this connection, Dr. Eiji Hamamoto, Professor of Pediat-
rics at Okayama University Hospital, thought that the
clinical effects might have resulted from a metal or metal-
loid poisoning [7,14]. On August 23rd, Dr. Hamamoto
further speculated that arsenic could be the culprit due to
the specific clinical picture. He asked the department of
Forensic Medicine of Okayama University to examine
whether arsenic existed in the Morinaga dried milk, and
this prediction was confirmed. On the following day, he
presented the combined evidence to the public on behalf
of the Director of the Health Department, Okayama Pre-
fectural Government: (1) The patients showed fever, skin
pigmentation, hepatomegaly, and anemia, which were all
in accordance with clinical symptoms of arsenic poison-
ing; (2) arsenic was identified from the Morinaga dried
milk that the patients had ingested; and, (3) although
there was insufficient evidence for beneficial effects,
administration of British anti-Lewisite (BAL) could be rec-
ommended as a tentative treatment against arsenic poi-
soning.
In the course of the day, the sale of this milk was banned
in Japan. On the following day, arsenic was detected in the
liver tissue and hair of a deceased infant. Due to BAL treat-
ment, the patients' conditions improved, and the number
of deaths immediately decreased [15]. In addition, after
three mice were fed a diet with Morinaga dried milk for 7–
9 days, histochemical examinations of the dead mice
revealed detectable amounts of arsenic in the liver [7].
Source of Arsenic Exposure
The arsenic poisoning was linked with MF-marked dried
milk that was manufactured at the Tokushima plant (i.e.,
Morinaga F-plant). Morinaga records showed that the
dried milk had been contaminated with arsenic from
April 13th, 1955. The source was a disodium phosphate
product added to cow's milk as a stabilizer to preserve
constant acidity, but the particular industrial-grade diso-
dium phosphate was of low purity and contained five to
eight percent of arsenic (expressed as arsenous acid)
[7,15]. When the disodium phosphate additive used at
the plant was analyzed, it contained trisodium phosphate,
sodium arsenate, and several other impurities. According
to Nakagawa and Iibuchi [13], the additive was a byprod-
uct of the process in which aluminum was produced from
bauxite and consisted of approximately 45% crystal water,
14% P2O5, 28% Na2O, 2% V2O5, and 6% As2O5. At that
time, the Tokushima plant manufactured approximately
200,000 one-pound cans of dried milk per month. The
product was sold mainly in western Japan, and most of
the victims accordingly resided in the same area [16].
Some Morinaga dried milk also appeared on the market of
eastern Japan, including Tokyo, in August 1955, but most
of the cans were fortunately collected before being sold.
The final arsenic concentration (expressed as arsenous
acid) in MF dried milk was calculated to be between
0.001% and 0.007% (mean 0.003%) by the Hyogo Pre-
fectural Institute of Hygiene and between 0.0015% and
0.0020% by the Tokyo Metropolitan Institute of Hygiene
[12]. Although the arsenic content differed by lot number,
MF dried milk can be assumed to contain about 21–35 μg
arsenic per gram. Using the manufacturer's instructions
printed on the label, final milk concentrations can be cal-
culated to be 4.2–7.0 mg/L. For average milk consump-
tions, the daily arsenic intake would then be about 2.5 mg
for a 1-month-old infant, 3.2 mg for a 2-month-old
infant, and 4.6 mg for a 6-month-old infant [7]. On aEnvironmental Health: A Global Access Science Source 2006, 5:31 http://www.ehjournal.net/content/5/1/31
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body-weight basis, this dose corresponds to approxi-
mately 540 μg/kg body weight per day for 1-month-old
infant, 590 μg/kg body weight per day for 2-month-old
infant, and 610 μg/kg body weight per day for 6-month-
old infant. If 50% milk or other diluted milk preparations
were used, the arsenic exposures would be lower.
Although the duration of exposure was generally not
recorded, the appearance of cases during the summer
would have allowed as little as a few weeks of exposure.
More detailed information on total doses is available
from descriptive studies of case series.
Descriptive Studies of Acute Toxicity
In Okayama prefecture, poisoning cases occurred during
the period of August 8th 1955 to April 30th 1956 and led
to admission of 24 fatal cases, 2,005 surviving patients,
and 84 suspected patients with some symptoms of arsenic
poisoning but whose diagnosis was considered uncertain
[7]. Of these 2,113 patients, infants aged 6–10 months
predominated (N = 954), and males constituted 1,223 of
all patients (57.9%) (Figure 1). The age distribution in the
patients ranged from one month to 61 years. The first vic-
tim of MF dried milk seems to have appeared in April
1955, and the incidence reached the peak in July and
August of the same year.
It was difficult to estimate the total amount of arsenic
ingested in each case of MF dried milk poisoning, because
arsenic content differed somewhat among lots of dried
milk, the actual number of the dried milk cans purchased
by each family was unknown, and dried milk was often
consumed not only by infants but also by other house-
hold members. Based on data from patients whose diet
was based only on MF dried milk, the critical dose causing
clinical poisoning was estimated to be approximately five
cans (i.e., 5 pounds of dried milk). From the manufac-
turer's instructions, a two-month-old infant would con-
sume this amount in two-to-three weeks. The total dose
can then be calculated to be about 60 mg.
Table 1 represents clinical symptoms and signs observed
from 381 infant cases (320 outpatients and 61 inpatients)
that were examined at the Okayama University Hospital
[7]. All inpatients showed hepatomegaly but normal col-
loid reaction. Of the inpatients examined with electrocar-
diogram (ECG), almost half had abnormal ECG findings,
such as ST elevation, flat T or prolonged QT interval. Table
2 shows results of clinical examination and chemical anal-
yses from 59 inpatients [7]. Urinalysis showed erythrocy-
turia in several patients, while none had proteinuria.
Unfortunately, neuromotor dysfunction or dysesthesia
were impossible to assess in these pediatric patients.
Distribution of 2,113 cases of dried milk poisoning in Okayama Prefecture in 1955 Figure 1
Distribution of 2,113 cases of dried milk poisoning in Okayama Prefecture in 1955.
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Controversies About the Morinaga Dried Milk Poisoning
This poisoning incident happened during the early phase
of Japan's rapid economic growth during the post-World
War II period. At that time, most of the Japanese market
for milk substitutes was covered by three major compa-
nies, including the Morinaga Milk Industry Company,
and fierce competition demanded that production meth-
ods be optimized in regard to expenses. For this reason,
food safety concerns seemed to be disregarded by the food
manufacturing industry, judging from the fact that no
quality control or assessment of raw materials was con-
ducted by the company: Why did the Tokushima plant use
a crude byproduct containing arsenic as an additive with-
out due consideration? Also, if the company had used
fresh milk for the production of dried milk, a disodium
phosphate stabilizer would not have been required [15].
In the mid-1950s, the physicians concerned were not
aware of any potential health risks associated with infant
food. For this reason, only descriptive evidence was col-
lected on clinical presentations until the time when
arsenic was identified in the dried milk product. Likewise,
even after the MF dried milk was banned, no research was
carried out on arsenic levels in infant hair or urine. The
clinical researchers involved in the Morinaga dried milk
poisoning did not collect any data on exposure levels or
tissue concentrations. As the result, the evidence of the
Morinaga dried milk poisoning is severely limited in
regard to documentation of exposures or dose levels, and
no evidence is at hand to determine dose-response or
dose-effect relations of arsenic exposure. A similar situa-
tion occurred later on in regard to Minamata disease
(methylmercury poisoning) [17] and Kanemi rice oil poi-
soning (due to polychlorinated aromatic compounds,
Yusho) [18].
On October 9th 1955, a child health committee,
appointed by the Ministry of Health and Welfare, decided
upon the formal criteria for diagnosis of poisoning caused
by arsenic intake, as well as for identifying recovery [19].
The former criteria required skin pigmentation,
hepatomegaly, and abnormal changes in blood cell values
but was not based on drinking the arsenic-tainted
Morinaga dried milk [19]. Some physicians pointed out
that skin pigmentation, as compared to other symptoms,
was not necessarily associated with the estimated intake of
a toxic arsenic dose [15]. Thus, if a suspected case was to
be registered without skin pigmentation, a high level of
arsenic had to be proved in urine or hair of the case. The
Ministry of Health and Welfare reported a total of 12,131
victims, including 130 fatalities by June 9th 1956; how-
ever, a number of unregistered patients were not included
Table 1: Clinical symptoms and signs observed in 381 infants with Morinaga dried milk poisoning*
Number of patients with symptom Frequency
Fever 358 94.0%
Diarrhea 269 70.6%
Vomiting 125 32.8%
Cough 134 35.2%
Eye discharge 141 37.0%
Skin pigmentation 349 91.6%
Skin rash 151 39.4%
Skin desquamation 182 47.8%
Edema 58 15.2%
Abdominal distension 105 27.6%
*Data from Okayama University Hospital [7]
Table 2: Results of clinical examination of 61 inpatients with Morinaga dried milk poisoning*
Parameter Number abnormal among inpatients Frequency
Hepatomegaly 61/61 100%
Electrocardiogram 26/57 45.6%
Red blood cell count
<300 × 104/μl 35/59 59.3%
<200 × 104/μl 12/59 20.2%
White blood cell count
<5000/μl 25/59 42.4%
<3000/μl 5/59 8.5%
Erythrocyturia 14/59 23.7%
*Data from Okayama University Hospital [7]Environmental Health: A Global Access Science Source 2006, 5:31 http://www.ehjournal.net/content/5/1/31
Page 5 of 7
(page number not for citation purposes)
in the above figure [20], because most physicians did not
request examination of urine or hair for arsenic, which
was a tedious procedure at the time.
The ministerial committee judged that the disappearance
of acute symptoms due to arsenic poisoning was regarded
as a sign of complete cure. However, apparent resolution
of acute toxicity, according to medical standards in Japan
in those days, would be inadequate and erroneous as a cri-
terion for complete recovery [15,19]. Thus, a coordinated
follow-up study on child development should have been
performed to determine the long-term consequences of
slight brain edema, petecchial hemorrhage in the cerebel-
lum, and myelin sheath degeneration of the optic nerves,
which were observed on autopsy [7]. The news interest
faded, and no further publications about the disaster
appeared after the report by Hamamoto [7], thus reflect-
ing the belief that the victims were thought to have recov-
ered completely according to the above criteria [19].
Still, in March 1956, the Ministry of Health and Welfare
sent the prefectural governments a notice requiring
detailed medical checkups on patients with continued
signs of Morinaga dried milk poisoning and on "cured"
infants due to parental worries about prognosis and
sequelae [11,15]. The patients were judged according to
the presence or absence of acute effects of arsenic in regard
to their possible need for further medical treatment and
care, and most of them were therefore considered as cases
without sequelae at the time of the checkup. Thus, no fur-
ther follow-up was performed for many years.
In parallel, a third-party committee also favored the side
of the enterprise (i.e., Morinaga Milk Industry Company)
and did not recommend relief or support to the victims.
Likewise, the first trial judgment in the Tokushima District
Court applied the rule of reliance on reasonable conduct,
and passed a sentence of not guilty on the offending com-
pany.
Follow-up Studies
In 1969, Iibuchi and Nakagawa presented a study address-
ing the question "How are the infants who suffered from
Morinaga dried milk poisoning 14 years ago?" at the
meeting of Japanese Society of Public Health, and public
attention was again paid to the patients. Thereafter, sur-
veys of Morinaga milk poisoning patients began at several
places of western Japan [15,19]. Since most of approxi-
mately twenty reports did not include any control groups
or data on exposure levels, only two papers are reviewed
here.
In Kyoto, epidemiological survey (415 subjects), clinical
examination (292 subjects), and clinical psychological
testing (261 subjects) were carried out during the period
from December 1970 to July 1971 [15]. Poisoning victims
in Kyoto had a much higher rate of physical and mental
complaints than the control group; even average height in
the victims was less than that of controls of the same age
(Table 3). The prevalence of central nervous disorders,
such as epilepsy, minimal brain damage or mental retar-
dation, was increased in the victims. Also, the proportion
of victims with intelligence quotient (IQ) less than 85 was
higher than the anticipated from average values of the
Japan Educational Ministry Statistics (Table 3). Based on
these data, the authors concluded that the physical and
mental defects of the victims were the result of consump-
tion of arsenic-tainted Morinaga dried milk, and they
emphasized that these children had received no therapy
or support since then.
Another comparative survey was made among all children
born between January 1st, 1954 and December 31st, 1955
and brought up in a certain district of Hiroshima prefec-
ture in 1971 [19]. The children were divided into three
groups, namely those who had consumed the arsenic-
tainted milk, those who were brought up on various
brands of powdered milk from different companies, and
those fed only maternal milk. At age 14 years, the victims
had a lower IQ than their unexposed brothers and sisters.
The victim group also had a higher rate of severe retarda-
Table 3: Results of follow-up examination at adolescence of Morinaga dried milk poisoning victims in Kyoto [15]
Tests Frequency abnormal (Number abnormal/total number) Source of controls
Victims Controls
Proteinuria
Males 13.3% (25/174) 0.85% 16-year-old students in Kyoto
Females 11.7% (13/111) 1.20%
Electroencephalogram 13.6% (39/287) 8.6% 1st grade high school students aged 16–18 years
Hearing disability 17.3% (50/289) 0.11% 16-year-old students in Kyoto
Refraction anomaly 47.9% (134/280) 41.77% 16-year-old students in Kyoto
Intelligence quotient <85 20.6% (52/252) 2.04% Average value for JapanEnvironmental Health: A Global Access Science Source 2006, 5:31 http://www.ehjournal.net/content/5/1/31
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tion (IQ below 50) than the controls who had not con-
sumed the arsenic-tainted milk. Other, less remarkable
findings among these children are shown in Table 4[19].
Chronic Effects in Survivors of Morinaga Dried Milk 
Poisoning
The Hikari Association was established in April 1974,
based on the agreement by a tripartite meeting (i.e., the
victim group, Morinaga Milk Company, and Ministry of
Health and Welfare), as a public-interest juridical founda-
tion for relieving permanently the victims due to the
Morinaga dried milk poisoning incident [21]. The Associ-
ation reported that, by March 31st 2002, the total number
of the victims was 13,420; approximately 6,000 of them
have established contact with the Association. Of the 798
victims who have received welfare allowances from the
Association in 2001, 337 suffered from developmental
retardation; 129 suffered from various disabilities; 103
from mental disorders, and 33 from epilepsy.
Discussion
The review of the unfortunate Morinaga dried milk poi-
soning incident leads to several observations. First, food
safety considerations are imperative, in particular for
large-scale production of infant foods. A simple review of
the raw materials would have identified that the additive
contained a toxic material that should not occur in a food
product. Second, when infants sickened, the clinical facil-
ities and the health authorities were not prepared to han-
dle an epidemic, and countless numbers of cases probably
occurred because the source of the toxicant exposure was
only discovered with a substantial delay, despite the obvi-
ous connection with the milk substitute. Third, the clini-
cal criteria established by the governmental authorities
were rigid and misleading, and as a result, patients with
chronic effects were ignored and were not provided with
the treatment and support that they needed. Fourth, the
failure to collect exposure information and the absence of
registries and facilities for long-term follow-up of exposed
population groups, such as the Morinaga victims, has
made it impossible to determine the true extent of the
adverse health effects in the victims. Finally, the victims of
this unfortunate incident have not received the support
and compensation that they deserved.
The Morinaga milk incident also has international
aspects. Clearly, the unfortunate poisoning of thousands
of infants was not heralded by governmental agencies as
an illustrative case to support food safety measures. The
failure to prevent the arsenic poisonings was considered
embarrassing, and little effort was made to broadcast the
lessons outside of Japan. Only brief reports in English
have been published by Japanese scholars in international
scientific journals [22]. However, these reports have been
ignored by scientists abroad and by international agen-
cies. As also noted elsewhere [10], the World Health
Organization [3] and the US National Academy of Sci-
ences [2] have recently published extensive risk assess-
ment documents on arsenic, but developmental
neurotoxicity is not offered a single sentence. Somehow,
the world has therefore seemed to turn the blind eye to
this very serious poisoning incident.
Arsenic is a well-documented cause of peripheral neuro-
toxicity in adults [4-6,22]. Recent cross-sectional studies
of children at school age have reported cognitive deficits
associated with increased drinking water contamination
levels [23] and increased urinary arsenic concentrations
[24]. Similar results were obtained in children with
arsenic exposure from a smelter [25]. A possible joint
Table 4: Abnormal clinical findings from the follow-up study in Hiroshima [19]
Parameter Number abnormal/total number (frequency)
Bottle-fed Morinaga milk Bottle-fed other milk Breast-fed
Dermatology 9/32 (28.1%) 5/26 (19.2%) 6/48 (12.5%)
Electrocardiogram 12/33 (36.4%) 8/25 (32.0%) 26/48 (54.2%)
Electroencephalogram 16/33 (48.5%) 8/26 (30.8%) 12/48 (25.0%)
X-ray of forearm and hand 12/29 (41.4%) 9/27 (33.3%) 24/48 (50.0%)
X-ray of foot 19/29 (65.5%) 23/27 (85.2%) 40/48 (83.3%)
Ophthalmologya
Myopia 17/56 (30.4%) 20/52 (38.5%) 32/96 (33.3%)
Hyperopia 4/56 (7.1%) 4/52 (7.7%) 6/96 (6.3%)
Glasses-corrected vision <1.0 7/56 (12.5%) 2/52 (3.8%) 3/96 (3.1%)
Dentistry
Periodontal disease 15/29 (51.7%) 15/26 (57.7%) 31/48 (64.6%)
DMFb 36.3% 35.4% 29.9%
Dentine abnormalityb 14.2% 7.0% 11.1%
a Denominator is the number of eyes
b Proportion to the number examined teeth (DMF = decayed, missing, and filled teeth)Environmental Health: A Global Access Science Source 2006, 5:31 http://www.ehjournal.net/content/5/1/31
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adverse effect on IQ caused by arsenic and manganese
exposures was suggested by hair contaminant concentra-
tions in children living near a hazardous waste site [26].
These more recent data are externally consistent and fit
with the high-exposure findings from Japan, although
none of the above studies refer to the Japanese evidence.
The dose required to generate serious neurotoxic effects in
the exposed Japanese infants was estimated to be of the
order of magnitude of 60 mg, and the arsenic concentra-
tions in the contaminated milk mixture (if not diluted)
was estimated as 4.2 – 7.0 mg/L. This level may be com-
pared to arsenic concentrations in contaminated drinking
water in affected geographical areas, such as the Bengal,
where the highest levels may approach or exceed 1 mg/L
[3,24]. Although the Morinaga evidence does not allow a
detailed dose-response relationship, the serious conse-
quences in many victims suggest that the risk of develop-
mental neurotoxicity must be taken into account when
evaluating the potential adverse health effects of arsenic
exposures.
Conclusion
The Morinaga milk poisoning event provides clear-cut evi-
dence for hazard assessment of developmental neurotox-
icity. Clinical poisoning with severe neurobehavioral
sequelae occurred when infants were exposed to total
doses of about 60 mg from milk mixtures during a period
of a few weeks. This evidence amply demonstrates the
need to consider neurotoxicity as a key concern in regard
to environmental arsenic exposure. Further, Morinaga evi-
dence provides weighty support to several suggestive
cross-sectional studies from various settings in regard to
the subclinical neurotoxic effects of arsenic. The effects of
arsenic on central nervous system development therefore
need to be further explored and included in future risk
assessments.
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